Psoriasis drug shows promise for heart health in small study
NCT ID NCT04271540
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether tildrakizumab, a drug already approved for psoriasis, can improve blood flow to the heart in people with moderate-to-severe psoriasis. 36 adults took the drug for 6 months, and researchers measured heart function using special scans. The goal was to see if reducing skin inflammation might also lower the risk of heart problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Putting Patients' priorities first: a new approach to ease the burden of multiple chronic illnesses
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?
- Virtual fitness for aging hearts: a new frontier in cardiac rehab?